Translation of CNP-302 to the clinic for tumor immunotherapy due to its direct ability to activate NK cells and CD8+ T cells and ability to enhance the response to anti-PD-1 treatment is facilitated by the fact that it is easily GMP manufacturable and that i.v. administration of gliadin-encapsulating PLGA nanoparticles was proven safe in celiac disease patients (37). Here, CD8A is linked to celiac disease.